Of the few pre­clin­i­cal IPOs, Metageno­mi keeps de­tails about IND plans close

There’s no word yet on when Metageno­mi will en­ter the clin­ic.

In its first quar­ter­ly up­date as a pub­lic com­pa­ny, the Cal­i­for­nia biotech said Wednes­day that its cash run­way is set to take it in­to 2027 and bankroll two INDs along the way, but it was mum on when the first study could be­gin.

That didn’t sur­prise an­a­lysts since Metageno­mi went pub­lic last month in one of the most high-pro­file pre­clin­i­cal IPOs in re­cent mem­o­ry. The com­pa­ny is at­tempt­ing to find new en­zymes and cre­ate gene-edit­ing tools.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER